Oncology and Hematology - Prova Education

Episodes 17-32 of 92

Optimal Sequencing of ADCs in Endocrine Refractory HR+/HER2- Metastatic Breast Cancer
Optimal Sequencing of ADCs in Endocrine Refractory HR+/HER2- Metastatic Breast Cancer
CME/CE
Optimal Sequencing of ADCs in Endocrine Refractory HR+/HER2- Metastatic Breast Cancer
0.50 credits
- Javier Cortes, MD, PhD
- Komal Jhaveri, MD, FACP
0.50 credits
TAR-210 vs Intravesical Chemotherapy in Intermediate-Risk Non–Muscle-Invasive Bladder Cancer With Susceptible FGFR Alterations: MoonRISe-1
TAR-210 vs Intravesical Chemotherapy in Intermediate-Risk Non–Muscle-Invasive Bladder Cancer With Susceptible FGFR Alterations: MoonRISe-1
Oncology and Hematology
TAR-210 vs Intravesical Chemotherapy in Intermediate-Risk Non–Muscle-Invasive Bladder Cancer With Susceptible FGFR Alterations: MoonRISe-1
Phase-3 SunRISe-2: TAR-200 Plus Cetrelimab Versus Chemoradiotherapy in Muscle-Invasive Bladder Cancer
Phase-3 SunRISe-2: TAR-200 Plus Cetrelimab Versus Chemoradiotherapy in Muscle-Invasive Bladder Cancer
Oncology and Hematology
Phase-3 SunRISe-2: TAR-200 Plus Cetrelimab Versus Chemoradiotherapy in Muscle-Invasive Bladder Cancer
Updates From SunRISe-3: TAR-200 Plus Cetrelimab or TAR-200 Versus Intravesical BCG in High-Risk Non–Muscle-Invasive Bladder Cancer
Updates From SunRISe-3: TAR-200 Plus Cetrelimab or TAR-200 Versus Intravesical BCG in High-Risk Non–Muscle-Invasive Bladder Cancer
Oncology and Hematology
Updates From SunRISe-3: TAR-200 Plus Cetrelimab or TAR-200 Versus Intravesical BCG in High-Risk Non–Muscle-Invasive Bladder Cancer
TAR-200 vs Intravesical Chemotherapy After BGC: Phase 3 Sun-RISe-5 in Non–Muscle-Invasive Bladder Cancer
TAR-200 vs Intravesical Chemotherapy After BGC: Phase 3 Sun-RISe-5 in Non–Muscle-Invasive Bladder Cancer
Oncology and Hematology
TAR-200 vs Intravesical Chemotherapy After BGC: Phase 3 Sun-RISe-5 in Non–Muscle-Invasive Bladder Cancer
SunRISe-1: TAR-200 in BCG-Unresponsive High-Risk Bladder Cancer
SunRISe-1: TAR-200 in BCG-Unresponsive High-Risk Bladder Cancer
Oncology and Hematology
SunRISe-1: TAR-200 in BCG-Unresponsive High-Risk Bladder Cancer
Real-World Sequencing and Survival in Locally Advanced Prostate Cancer
Real-World Sequencing and Survival in Locally Advanced Prostate Cancer
Oncology and Hematology
Real-World Sequencing and Survival in Locally Advanced Prostate Cancer
Evolving Trends in Germline Genetic Testing for Prostate Cancer
Evolving Trends in Germline Genetic Testing for Prostate Cancer
Oncology and Hematology
Evolving Trends in Germline Genetic Testing for Prostate Cancer
Updates from Apa-RP: Apalutamide and ADT in High-Risk Localized Prostate Cancer
Updates from Apa-RP: Apalutamide and ADT in High-Risk Localized Prostate Cancer
Oncology and Hematology
Updates from Apa-RP: Apalutamide and ADT in High-Risk Localized Prostate Cancer
GPRC5D-Targeted Bispecifics in Relapsed/Refractory Multiple Myeloma: Practical Expert Consensus on a New Target with Unique Adverse Events
GPRC5D-Targeted Bispecifics in Relapsed/Refractory Multiple Myeloma: Practical Expert Consensus on a New Target with Unique Adverse Events
CME/CE
GPRC5D-Targeted Bispecifics in Relapsed/Refractory Multiple Myeloma: Practical Expert Consensus on a New Target with Unique Adverse Events
0.25 credits
- Jeffrey V. Matous, MD
0.25 credits
GPRC5D-Targeted Bispecifics in Relapsed/Refractory Multiple Myeloma: Practical Expert Consensus on a New Target with Unique Adverse Events
GPRC5D-Targeted Bispecifics in Relapsed/Refractory Multiple Myeloma: Practical Expert Consensus on a New Target with Unique Adverse Events
CME/CE
GPRC5D-Targeted Bispecifics in Relapsed/Refractory Multiple Myeloma: Practical Expert Consensus on a New Target with Unique Adverse Events
0.50 credits
- Jeffrey V. Matous, MD
- Donna Catamero, NP
- Ajai Chari, MD
0.50 credits
Applying SDM to Personalize Treatment Discussions on Recurrence Risk Reduction in Patients with Early-Stage Melanoma
Applying SDM to Personalize Treatment Discussions on Recurrence Risk Reduction in Patients with Early-Stage Melanoma
CME/CE
Applying SDM to Personalize Treatment Discussions on Recurrence Risk Reduction in Patients with Early-Stage Melanoma
0.25 credits
- Meghan Mooradian, MD
0.25 credits
Emerging ADC Therapies for NSCLC: Anticipating AEs Reported in Clinical Trials
Emerging ADC Therapies for NSCLC: Anticipating AEs Reported in Clinical Trials
MinuteCE®
Emerging ADC Therapies for NSCLC: Anticipating AEs Reported in Clinical Trials
1.00 program credit
- Egbert Smit, MD
1.00 program credit
Risk Reduction and Management Protocols for Gastrointestinal Adverse Events With ADC Therapy in Breast Cancer
Risk Reduction and Management Protocols for Gastrointestinal Adverse Events With ADC Therapy in Breast Cancer
MinuteCE®
Risk Reduction and Management Protocols for Gastrointestinal Adverse Events With ADC Therapy in Breast Cancer
1.00 program credit
- Nadia Harbeck, MD, PhD
1.00 program credit
Gastrointestinal and Hematologic TEAEs Related to ADC Therapy in Gynecologic Cancers
Gastrointestinal and Hematologic TEAEs Related to ADC Therapy in Gynecologic Cancers
MinuteCE®
Gastrointestinal and Hematologic TEAEs Related to ADC Therapy in Gynecologic Cancers
1.00 program credit
- Susana Campos, MD, MPH
1.00 program credit
Optimal Management of ADC-Related Gastrointestinal AEs in NSCLC
Optimal Management of ADC-Related Gastrointestinal AEs in NSCLC
MinuteCE®
Optimal Management of ADC-Related Gastrointestinal AEs in NSCLC
1.00 program credit
- Egbert Smit, MD
1.00 program credit

2/6